Mycophenolate mofetil and mycophenolic acid for the treatment of eosinophilic fasciitis: report of two cases and literature review
Authors:
- Ilse Andrea Moreno-ArquietaIMIlse Andrea Moreno-Arquieta
- Jesus Alberto Cardenas-De la GarzaJGJesus Alberto Cardenas-De la Garza
- Jorge Antonio Esquivel-ValerioJEJorge Antonio Esquivel-Valerio
- Janett Riega-TorresJRJanett Riega-Torres
- Adrian Cuellar-BarbozaACAdrian Cuellar-Barboza
- Maira Elizabeth Herz-RuelasMHMaira Elizabeth Herz-Ruelas
- Jorge Ocampo-CandianiJOJorge Ocampo-Candiani
- Dionicio Angel Galarza-DelgadoDGDionicio Angel Galarza-Delgado
- 21 February 2021
- journal article
- case report
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (3) , 1765-1768
Abstract
Eosinophilic fasciitis (EF) is an uncommon autoimmune connective tissue disorder characterized by edema, erythema, and subsequent induration of the extremities. It is commonly treated with corticosteroids but there is no treatment ladder for immunosuppressants or steroid-sparing agents. We report two EF cases treated effectively with mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and present a literature review. We performed a MEDLINE search using the keywords ‘eosinophilic fasciitis’, ‘Shulman syndrome’, ‘mycophenolic acid’, or ‘mofetil mycophenolate’, and found 8 articles with 27 cases in which MMF or MPA was used. Twenty-nine cases were reviewed (2 reported herein and 27 from the literature search); all patients received a combination of systemic corticosteroids and MMF. MMF/MPA were given as a steroid-sparing agent in 27 (93.1%), in 1 (3.4%) as adjunctive therapy with other immunosuppressants, and in one, as monotherapy 1 (3.4%). Nineteen had a complete response, 6, a partial response, and 2 were unresponsive to diverse immunomodulators; in 2 cases, the outcome was not reported. MMF and MPA show promising therapeutic results and could be a treatment option to reduce corticosteroid related side effects.Keywords
This publication has 9 references indexed in Scilit:
- Mycophenolate Mofetil for Eosinophilic FasciitisJAMA Dermatology, 2020
- Baseline characteristics and long‐term outcomes of eosinophilic fasciitis in 89 patients seen at a single center over 20 yearsInternational Journal of Rheumatic Diseases, 2019
- Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of LiteratureThe Oncologist, 2019
- Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remissionDrugs in Context, 2018
- Generalized morphea/eosinophilic fasciitis overlap after epoxy exposureJAAD Case Reports, 2018
- Shulman disease (eosinophilic fasciitis) in X-linked agammaglobulinemiaPolish Journal of Pathology, 2016
- Mycophenolic acid in dermatology a century after its discoveryAustralasian Journal of Dermatology, 2014
- Eosinophilic Fasciitis in a Pediatric PatientJCR: Journal of Clinical Rheumatology, 2010
- Use of Infliximab, an Anti-Tumor Necrosis Alpha Antibody, for Inflammatory DermatosesJournal of Cutaneous Medicine and Surgery, 2003